期刊文献+

阿司匹林在阿尔茨海默病防治中作用机制研究进展 被引量:5

原文传递
导出
摘要 阿尔茨海默病(Alzheimer′s disease,AD)主要临床表现为进行性记忆力减退、认知功能障碍以及人格改变等症状,其主要病理改变是:大脑皮层及海马区的β淀粉样蛋白(amyloidβ-peptide,Aβ)在胞外积累并形成老年斑(senile plaque,SP)、脑神经细胞内tau蛋白异常聚集形成的神经元纤维缠结(neurofibrillary tangle,NFT)、神经元突触功能异常及锥体神经细胞的丢失。
出处 《中华临床医师杂志(电子版)》 CAS 2011年第14期4177-4179,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 上海市教委科研创新项目(10zs57)
  • 相关文献

参考文献22

  • 1丁正,周海霞.多奈哌齐联合阿司匹林治疗轻度Alzheimer病疗效观察[J].齐齐哈尔医学院学报,2010,31(17):2721-2722. 被引量:1
  • 2章卓,刘明华,秦大莲,肖顺汉,李华.阿司匹林与黄芪颗粒合用对大鼠Alzheimer’s模型炎症因子影响研究[J].四川生理科学杂志,2009,31(1):9-11. 被引量:6
  • 3郭振辉,洪新,毛宝龄,钱桂生,邹霞英,李艳春.阿斯匹林新的抗炎机制研究[J].中国危重病急救医学,2000,12(10):602-605. 被引量:9
  • 4Sven E. Nilsson,Boo Johansson,Sanna Takkinen,Stig Berg,Steven Zarit,Gerald McClearn,Arne Melander.Does aspirin protect against Alzheimer’s dementia? A study in a Swedish population-based sample aged ≥80 years[J]. European Journal of Clinical Pharmacology . 2003 (4)
  • 5Knapp M,Prince M.Dementia UK-a report into the prevalence and cost of dementia. . 2007
  • 6Wimo A,Winblad B,J nsson L.An estimate of the worldwide societal costs of dementia in 2005. Alzheimers Dement . 2007
  • 7Marwan N.Drug development for Alzheimer′s disease:where are we nowand where are we headed?. AmJ Geriatr Pharmacother . 2009
  • 8Etminan M,Gill S,Samii A.Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer′s disease:systematic review and meta-analysis of observational studies. British Medical Journal . 2003
  • 9AD2000 Collaborative Group,Bentham P,Gray R,et al.Aspirin in Alzheimer′s disease (AD2000):a randomised open-label trial. The Lancet Neurology . 2008
  • 10Hirohata M,Ono K,Naiki H,et al.Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer′sβ-amyloidfibrils in vitro. Neuropharmacology . 2005

二级参考文献19

  • 1刘佳福,刘振国.阿尔茨海默病炎症发病机制的研究进展[J].中风与神经疾病杂志,2004,21(5):471-472. 被引量:4
  • 2朱正禹,毕建忠,许顺良,王晓云,谢兆宏,杨萧荟.阿司匹林治疗前后Alzheimer病患者外周血细胞因子基因表达变化[J].山东医药,2004,44(22):3-5. 被引量:2
  • 3盛树力.老年痴呆分子生物学到临床诊治[M].北京:科学技术文献出版社,1999:128-135.
  • 4Khan TK,Alkon DI.An internally controlled peripheral biomarker for Alzheimer's disease:Erk1 and Erk2 responses to the inflammatory signal bradykinin[J].Proc Natl Acad Sci U S A,2006,103(35):13203-13207.
  • 5O'banion Mk,Finch CE.inflammatory mechanisms and anti-inflammatory therapy in alzheimer's disease,neurobiol aging[J],1996:17 (5):669-671.
  • 6Veld BA,Ruitenberg A,Hofman A,et al.Nonsteroedal antiflammatory drugs and the risk of Alzheimer's disease[J].N EnA J Nkd,2001,345(21):1515-1521.
  • 7Tskeda A,Loveman E,Clegg A,et al.A systematic review of the clinical effectiveness of donepezil,rivastigmine and galantamine on cognition.quality of life and adverse events in Alzheimer's disease[J].Int J Geriatr Psychiatry,2006,21(1):17-28.
  • 8Homma A,Imai Y,Tago H,et al.Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population; results from a 24-week,double-blind,placebo-controlled,randomized trial[J].Dement Geriatr Cogn Disord,2008,25(5) s 399-407.
  • 9Dantoine T,Auriacombe S,Sarazin M,et ai.Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment[J] ,Int J ClinPract,2006,60(1):10-118.
  • 10Shackelford R E,Mol Pharmacol,1997年,52卷,3期,421页

共引文献13

同被引文献60

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部